epoprostenol IV
Selected indexed studies
- Bosentan. (Expert Rev Cardiovasc Ther, 2004) [PMID:15151466]
- Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. (J Am Coll Cardiol, 2010) [PMID:20430262]
- Transition from IV epoprostenol to oral treprostinil in a patient with group 1 pulmonary arterial hypertension. (Am J Health Syst Pharm, 2021) [PMID:34100906]
_Worker-drafted node — pending editorial review._
Connections
epoprostenol IV is a side effect of
Sources
- Bosentan. (2004) pubmed
- Pharmacokinetic evaluation of continuous intravenous epoprostenol. (2010) pubmed
- Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. (2010) pubmed
- Treprostinil sodium Pharmacia. (2002) pubmed
- Transition from IV epoprostenol to oral treprostinil in a patient with group 1 pulmonary arterial hypertension. (2021) pubmed
- Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension. (2013) pubmed
- Evidence for the Use of Epoprostenol to Treat Raynaud's Phenomenon With or Without Digital Ulcers. (2016) pubmed
- IV epoprostenol for systemic sclerosis. (2000) pubmed
- Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. (2014) pubmed
- IV epoprostenol in Gaucher's disease. (2000) pubmed